Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function.
Pavord ID, Siddiqui S, Papi A, Corren J, Sher LD, Bardin P, Langton D, Park HS, Rice MS, Deniz Y, Rowe P, Staudinger HW, Patel N, Ruddy M, Graham NMH, Teper A.
Pavord ID, et al.
J Asthma Allergy. 2020 Dec 16;13:701-711. doi: 10.2147/JAA.S275068. eCollection 2020.
J Asthma Allergy. 2020.
PMID: 33364789
Free PMC article.
RESULTS: In patients with elevated baseline eosinophils, dupilumab 200 mg and 300 mg q2w vs placebo reduced severe exacerbation rates by 50% (P=0.06) and 67% (P=0.001), respectively, in those with medium-dose ICS/FEV(1)% predicted 60-90%, and by 59% (P<0.001) and 47% (P=0.006) …
RESULTS: In patients with elevated baseline eosinophils, dupilumab 200 mg and 300 mg q2w vs placebo reduced severe exacerbation rates by 50% …